Ligand Pharmaceuticals, Inc. (LGND)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

3911 SORRENTO VALLEY BLVD SAN DIEGO, CA 92121

Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that focuses on drug discovery and early-stage development of pharmaceuticals that address critical unmet medical needs or that are more effective and/or safer than existing therapies. The Company also has research and development collaborations for its product candidates with global pharmaceutical companies. These collaborations include ongoing clinical programs at Bristol-Myers Squibb (BMS), GlaxoSmithKline (GSK), Pfizer, Merck & Co. (Merck), Roche, Cephalon and Celgene. These partnered product candidates are being studied for the treatment of market indications, such as thrombocytopenia, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), asthma, osteoporosis, menopausal symptoms and Alzheimer's disease. On December 23, 2009, it acquired Neurogen Corporation (Neurogen).

Data as of 2021-05-08 10:34:03 -0400
Market Cap2.175 Billion Shares Outstanding16.652 Million Avg 30-day Volume127.581 Thousand
P/E Ratio-728.67494 Dividend Yield EPS-0.184
Price/Sales11.67 Debt to Equity1.92 EBITDA32.173 Million
Price to Book Value3.07 Forward PE21.23 Enterprise Value2.213 Billion
Total Cash411.186 Million Current Debt100.111 Million Gross Profit156 Million
BETA0.84362 52-week High/Low219.75 / 78.26 Next Earnings Date2021-08-03 Price to Cash FLow (P/CF) 136.7967
Data provided by IEX Cloud
View SEC Filings from LGND instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 3 -33.33% 1 (0.06%) 2 (0.12%) -50.0%
Funds Holding: 235 248 -5.24% 54 (3.24%) 63 (3.92%) -14.29%
13F shares: 22.776 Million 22.814 Million -0.17% 6.268 Million 6.439 Million -2.65%
% Ownership 38.9776 40.0377 -2.65%
New Positions: 29 30 -3.33% 6 9 -33.33%
Increased Positions 81 90 -10.0% 22 26 -15.38%
Closed Positions 41 39 5.13% 15 16 -6.25%
Reduced Positions 90 96 -6.25% 22 27 -18.52%
Total Calls 322.998 Thousand 128.967 Thousand 150.45% 154 Thousand 26.3 Thousand 485.55%
Total Puts 1.751 Million 1.251 Million 39.88% 1.31 Million 779.7 Thousand 67.97%
PUT/CALL Ratio 5.42 9.7 -44.12% 8.5 29.65 -71.33%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding LGND (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LGND BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

4.8 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KOZARICH JOHN W

  • Director
34,152 2021-05-11 3

HIGGINS JOHN L CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
337,848 2021-02-15 8

FOEHR MATTHEW W PRESIDENT AND COO

  • Officer
165,100 2021-02-15 4

BERKMAN CHARLES S SVP, GEN. COUNSEL & SECRETARY

  • Officer
27,891 2021-02-15 5

KORENBERG MATTHEW E EVP,FINANCE & STRATEGY AND CFO

  • Officer
39,443 2021-02-15 4

DAVIS TODD C

  • Director
50,152 2021-02-10 3

SABBA STEPHEN L

  • Director
24,431 2021-02-09 2

PATEL SUNIL

  • Director
28,190 2020-11-02 2

ARYEH JASON

  • Director
124,653 2020-06-10 1

LAMATTINA JOHN L

  • Director
24,768 2020-06-10 1

GRAY NANCY RYAN

  • Director
3,072 2020-06-10 1

BOYCE SARAH

  • Director
2,262 2020-06-10 1

GOLDMAN SACHS GROUP INC

GOLDMAN SACHS & CO. LLC

686,330 2020-02-03 0

HERMAN MELANIE J DIRECTOR OF ACCOUNTING

  • Officer
3,454 2016-06-30 0

KNOTT DAVID M

  • Director
1,265,918 2015-08-17 0

DESILVA NISHAN M VP, FINANCE & STRATEGY AND CFO

  • Officer
22,282 2015-05-12 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

LAMPERT MARK N

  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
No longer subject to file 2014-03-24 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

INVESTMENT 10 LLC

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
6,978,580 2014-02-18 0

SHARP JOHN P VP FINANCE AND CFO

  • Officer
17,667 2014-02-12 0

INVESTMENT 10 LLC

  • SEE EXPLANATION OF RESPONSES
3,582,065 2013-01-01 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES
741,627 2012-10-26 0

KAZMI SYED VP, BUS. DEV. & STRATEGIC PLAN

  • Officer
18,230 2012-02-09 0

MEGLASSON MARTIN V-P, DISCOVERY RESEARCH

  • Officer
102,250 2010-05-11 0

BURAKOFF STEVEN J

  • Director
15,000 2009-05-29 0

DZIEWANOWSKA ZOFIA E VP, CLINICAL RESEARCH

  • Officer
33,977 2009-02-25 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
16,006,215 2009-01-23 0

PEACOCK BRUCE

  • Director
10,000 2008-12-23 0

LIGAND PHARMACEUTICALS INC

  • Director
10,000 2008-08-04 0

GREETHAM ELIZABETH M

  • Director
10,000 2008-05-29 0

PERRY JEFFREY R

  • Director
33,953 2008-05-29 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

KOZARICH JOHN W - Director

2021-05-13 20:57:13 -0400 2021-05-11 M 4,835 $10.12 a 34,543 direct

KOZARICH JOHN W - Director

2021-05-13 20:57:13 -0400 2021-05-11 M 4,835 d 0 direct

KOZARICH JOHN W - Director

2021-05-13 20:57:13 -0400 2021-05-11 F 391 $128.56 d 34,152 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
LIGAND PHARMACEUTICALS LGND 2021-05-14 22:15:03 UTC -0.2 0.25 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 21:45:03 UTC -0.2 0.25 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 21:15:03 UTC -0.2 0.25 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 20:45:03 UTC -0.2 0.25 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 20:15:04 UTC -0.2 0.25 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 19:45:02 UTC -0.2 0.25 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 19:15:03 UTC -0.2 0.25 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 18:45:03 UTC -0.2 0.25 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 18:15:03 UTC -0.2 0.25 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 17:45:03 UTC -0.2 0.25 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 17:15:03 UTC -0.2 0.25 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 16:45:03 UTC -0.2048 0.2548 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 16:15:03 UTC -0.2048 0.2548 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 15:45:03 UTC -0.2048 0.2548 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 15:15:02 UTC -0.2048 0.2548 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 14:45:04 UTC -0.2167 0.2667 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 14:15:03 UTC -0.2167 0.2667 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 13:45:03 UTC -0.2167 0.2667 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 13:15:03 UTC -0.2167 0.2667 550000
LIGAND PHARMACEUTICALS LGND 2021-05-14 12:45:03 UTC -0.2167 0.2667 550000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
THE LAZARD FUNDS, INC.- Lazard Enhanced Opportunities Portfolio LGND -155.0 shares, $-15414.75 2020-12-31 N-PORT
JNL Series Trust- JNL Multi-Manager Alternative Fund LGND -1098.0 shares, $-109196.1 2020-12-31 N-PORT
FundVantage Trust- Gotham Enhanced Index Plus Fund LGND -6.0 shares, $-436.32 2020-03-31 N-PORT
FundVantage Trust- Gotham Defensive Long Fund LGND -62.0 shares, $-4508.64 2020-03-31 N-PORT
AQR Funds- AQR Large Cap Relaxed Constraint Equity Fund LGND -465.0 shares, $-46286.1 2019-09-30 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund LGND -43.0 shares, $-3126.96 2020-03-31 N-PORT
AMERICAN BEACON FUNDS- American Beacon SSI Alternative Income Fund LGND -1370.0 shares, $-136246.5 2020-12-31 N-PORT
Morningstar Funds Trust- Morningstar Alternatives Fund LGND -1128.0 shares, $-209074.8 2021-01-29 N-PORT
Calamos Investment Trust/IL- Calamos Market Neutral Income Fund LGND -15000.0 shares, $-2780250.0 2021-01-31 N-PORT
UBS RELATIONSHIP FUNDS- UBS U.S. EQUITY ALPHA RELATIONSHIP FUND LGND -18048.0 shares, $-2018668.8 2020-06-30 N-PORT
Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund LGND -3259.0 shares, $-483048.98 2021-02-26 N-PORT

Elevate your investments